Pilot study evaluating the feasibility of stereotactic body radiation therapy for canine anal sac adenocarcinomas

2021 ◽  
Author(s):  
Michaela Swan ◽  
Deanna Morrow ◽  
Michael Grace ◽  
Natalie Adby ◽  
David Lurie
Keyword(s):  
Radiation Therapy ◽  
Pilot Study ◽  
Stereotactic Body Radiation Therapy ◽  
Stereotactic Body Radiation ◽  
Anal Sac

scholarly journals A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions

Cancer ◽  
2008 ◽  
Vol 112 (3) ◽  
pp. 650-658 ◽  
Author(s):  
Michael T. Milano ◽  
Alan W. Katz ◽  
Ann G. Muhs ◽  
Abraham Philip ◽  
Daniel J. Buchholz ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pilot Study ◽  
Stereotactic Body Radiation Therapy ◽  
Curative Intent ◽  
Stereotactic Body Radiation ◽  
Prospective Pilot Study

A pilot study of AMP-224—a PD-1 inhibitor—in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. TPS788-TPS788 ◽  
Author(s):  
Austin G. Duffy ◽  
Oxana V. Makarova-Rusher ◽  
Suzanne Fioravanti ◽  
Melissa Walker ◽  
Aradhana Venkatesan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Radiation Therapy ◽  
Pilot Study ◽  
Metastatic Colorectal Cancer ◽  
Tumor Immunity ◽  
Stereotactic Body Radiation Therapy ◽  
Cytotoxic T Cells ◽  
Stereotactic Body Radiation ◽  
Activated T Cell

TPS788 Background: AMP-224, a B7-DC Fc fusion protein, binds to PD-1, an inhibitory receptor that is present on the cell surface of exhausted, activated, effector, and memory T cells. AMP-224 has a unique mechanism of action in that it binds specifically to PD-1HI T cells (chronically stimulated / exhausted T cells) but not to PD-1LOcells which represent the normal activated T cell population. Several preclinical studies have documented an increase in peripheral antitumor immunity following radiation, a phenomenon known as the “abscopal effect”. Tumor PD-L1 expression has also been shown to be induced by radiation, which can suppress the anti-tumor immune response. Inhibition of PD-1/PDL-1 axis has been shown to improve anti-tumor immunity by blocking the tumor-mediated suppression of cytotoxic T cells. The aim of the study is to evaluate whether the anti-tumor immunity of anti-PD1 therapy (with AMP-224) can be enhanced by radiation therapy. Methods: Patients with histologically confirmed metastatic colorectal cancer to liver are being enrolled to this pilot study. The objectives are to determine the safety, tolerability and feasibility of AMP-224 in combination with stereotactic body radiation therapy (SBRT) to metastatic hepatic metastasis in patients with advanced colorectal cancer. Select eligibility are as follows: at least 1 measurable metastatic hepatic lesion by RECIST 1.1 criteria and amenable to SBRT. Patient must have progressed on or been intolerant of at least one prior oxaliplatin- and/or irinotecan-containing regimen and have metastatic lesions that are not amenable to curative resection; ECOG ≤ 1; Life expectancy of greater than 3 months. Acceptable organ and bone marrow function. No active or prior documented autoimmune or inflammatory disorders. Clinical trial information: awaited.

scholarly journals Fatigue in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) to the Lung: A Pilot Study

2018 ◽  
Vol 49 (2) ◽  
pp. 5
Author(s):  
Jennifer Su ◽  
Darby Erler ◽  
Bonnie Bristow ◽  
Patrick Cheung ◽  
Ian Poon ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pilot Study ◽  
Stereotactic Body Radiation Therapy ◽  
Stereotactic Body Radiation
Sign in / Sign up

Export Citation Format

Share Document